Niflumic and Sulindac share 9 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.231 means 23% of the combined target set is bound by both compounds. The IDF-weighted score of 0.172 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Niflumic and Sulindac have in common?
Niflumic and Sulindac share 9 molecular targets with a Jaccard similarity of 23%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Niflumic and Sulindac be combined?
Niflumic and Sulindac share 9 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Niflumic or Sulindac?
Both Niflumic and Sulindac have substantial PubMed research. View their individual profiles for full evidence scores.